Table 1.
Tumor and treatments characteristics
| Characteristic | |
|---|---|
| Histopathology (%) | |
| HCC | 21 (20.2) |
| Neuroendocrine | 77 (74) |
| Adrenocortical carcinoma | 5 (4.8) |
| Medullary thyroid cancer | 1 (1) |
| Baseline (%) tumor density (HU) | 43.77 ± 6.10 |
| <45 | 53 (51) |
| >45 | 51 (49) |
| Location (%) | |
| Segment 1 | 6 (5.8) |
| Segment 2 | 12 (11.5) |
| Segment 3 | 13 (12.5) |
| Segment 4 | 17 (16.3) |
| Segment 5 | 6 (5.8) |
| Segment 6 | 18 (17.3) |
| Segment 7 | 12 (11.5) |
| Segment 8 | 14 (13.5) |
| Cross–multiple segment | 6 (5.8) |
| Distribution (%) | |
| Multifocal | 93 (89.4) |
| Unifocal | 11 (10.6) |
| Particles (%) | |
| Embosphere | |
| 40–120 μm | 23 (22.1) |
| 100–300 μm | 51 (49) |
| 300–500 & 500–700 (μm) | 1 (1) |
| Bead Block (100–300 μm) | 3 (2.9) |
| Embosphere & PVA (100 μm) | 16 (15.4) |
| Bead Block & PVA | 5 (4.8) |
| LC Bead (100–300 μm) & Bead Block | 5 (4.8) |
| Catheter for TAE (%) | |
| Microcatheter | 101 (97.1) |
| Diagnostic catheter | 3 (2.9) |
| Index (range) tumor nos./patient | 3.35 ± 3.10 (1–14) |
| Size (range) mean + SD (mm) | 35.81 ± 26.38 (10.04–165) |
| <30 mm | 59 (56.7) |
| >30 mm | 45 (43.3) |